Peripheral T Cell Development and Immunophenotyping of Twins with Heterozygous FOXN1 Mutations.
Peripheral T Cell Development and Immunophenotyping of Twins with Heterozygous FOXN1 Mutations. Immunohorizons. 2024 Jul 01; 8(7):492-499.
PMID: 39008056
A severe case of delayed transfusion reaction in a patient with sickle cell disease while preparing for allogeneic stem cell transplant.
A severe case of delayed transfusion reaction in a patient with sickle cell disease while preparing for allogeneic stem cell transplant. Pediatr Blood Cancer. 2024 Aug; 71(8):e31086.
PMID: 38753388
Velociraptor: Cross-Platform Quantitative Search Using Hallmark Cell Features.
Velociraptor: Cross-Platform Quantitative Search Using Hallmark Cell Features. bioRxiv. 2024 May 04.
PMID: 38746337
Curative Therapies for Sickle Cell Disease.
Curative Therapies for Sickle Cell Disease. Pediatr Ann. 2024 Feb; 53(2):e56-e61.
PMID: 38302122
Approach to Diagnosing Inborn Errors of Immunity.
Approach to Diagnosing Inborn Errors of Immunity. Rheum Dis Clin North Am. 2023 11; 49(4):731-739.
PMID: 37821192
Systems Immunology Analyses of STAT1 Gain-of-Function Immune Phenotypes Reveal Heterogeneous Response to IL-6 and Broad Immunometabolic Roles for STAT1.
Systems Immunology Analyses of STAT1 Gain-of-Function Immune Phenotypes Reveal Heterogeneous Response to IL-6 and Broad Immunometabolic Roles for STAT1. Immunohorizons. 2022 07 15; 6(7):447-464.
PMID: 35840326
The role of biomarkers in risk stratification, treatment and outcome in acute GVHD.
The role of biomarkers in risk stratification, treatment and outcome in acute GVHD. Curr Opin Hematol. 2021 11 01; 28(6):401-407.
PMID: 34475350
Outcomes of pediatric patients with therapy-related myeloid neoplasms.
Outcomes of pediatric patients with therapy-related myeloid neoplasms. Bone Marrow Transplant. 2021 12; 56(12):2997-3007.
PMID: 34480120
Immunodeficiency and bone marrow failure with mosaic and germline TLR8 gain of function.
Immunodeficiency and bone marrow failure with mosaic and germline TLR8 gain of function. Blood. 2021 05 06; 137(18):2450-2462.
PMID: 33512449
BCR-ABL1-like B-Lymphoblastic Leukemia/Lymphoma with FOXP1-ABL1 Rearrangement: Comprehensive Laboratory Identification Allowing Tyrosine Kinase Inhibitor Use.
BCR-ABL1-like B-Lymphoblastic Leukemia/Lymphoma with FOXP1-ABL1 Rearrangement: Comprehensive Laboratory Identification Allowing Tyrosine Kinase Inhibitor Use. Lab Med. 2019 Oct 10; 50(4):401-405.
PMID: 30938769